Diagnosing Lyme borreliosis, despite years of standardization, continues to encounter difficulties. They result primarily from the lack of a good marker of active infection and one helpful in assessing the effectiveness of the treatment. So far, a certain diagnosis of Lyme borreliosis can be made only in a patient with erythema migrans (EM). Unfortunately, this symptom occurs only in some patients. According to the recommendations of the Polish Society of Epidemiologists and Doctors of Infectious Diseases, the effectiveness of treatment is determined by the disappearance of clinical symptoms. For this reason, for years, we have been looking for highly sensitive and diagnostically specific laboratory markers. These would allow for rapid identification of fresh infections with Borrelia spirochetes as well as simple monitoring of treatment efficacy. According to many of the recently published publications, the solution to the second of the presented problems may be the measurement of IgG antibodies to the surface antigen of Borrelia burgdorferi s.l. VlsE / C6.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.